Delving into the Latest Updates on A. Menarini China Holding Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

β1-adrenergic receptor(Beta-1 adrenergic receptor)	1

Primary objective: To evaluate the PK characteristics of avanafil 50 mg, 100 mg and 200 mg after single and multiple administration in healthy Chinese adult male subjects. Secondary objective: To evaluate the safety and tolerability characteristics of avanafil 50 mg, 100 mg and 200 mg after single and multiple administration in healthy Chinese adult male subjects.

Start Date-

Sponsor / Collaborator

A. Menarini China Holding Co., Ltd.

CTR20192725 / Active, not recruitingPhase 1

一项在中国健康受试者中评价奈必洛尔 5 mg 单次和多次给药后药代动力学和安全性的单中心、开放设计的I 期研究。

[Translation] A single-center, open-label phase I study was conducted to evaluate the pharmacokinetics and safety of nebivolol 5 mg after single and multiple doses in healthy Chinese subjects.

主要目的：在中国健康成年受试者中评价奈必洛尔 5 mg 单次给药和多次给药后的 PK 特征。次要目的：在中国健康成年受试者中评估奈必洛尔 5 mg 单次和多次给药后的安全性和耐受性。

[Translation]

Primary objective: To evaluate the PK characteristics of nebivolol 5 mg after single and multiple doses in healthy Chinese adult subjects. Secondary objective: To evaluate the safety and tolerability of nebivolol 5 mg after single and multiple doses in healthy Chinese adult subjects.

Start Date05 Jul 2021

Sponsor / Collaborator

A. Menarini China Holding Co., Ltd.

CTR20191808 / RecruitingPhase 3

一项随机、双盲、双模拟、多中心、活性药物对照比较奈必洛尔与比索洛尔在中国轻度至中度原发性高血压患者中的疗效与安全性的 III 期研究

[Translation] A randomized, double-blind, double-dummy, multicenter, active-controlled phase III study comparing the efficacy and safety of nebivolol and bisoprolol in Chinese patients with mild to moderate essential hypertension

这项研究旨在评估奈必洛尔相较于比索洛尔在治疗患有轻度至中度高血压的中国患者时的疗效的非劣效性与安全性。主要目的：评估奈必洛尔相较于比索洛尔在治疗轻度至中度原发性高血压患者中的抗高血压疗效的非劣效性。次要目的：评估奈必洛尔相较于比索洛尔在轻度至中度高血压患者中的安全性。

[Translation]

This study aims to evaluate the non-inferiority and safety of nebivolol compared with bisoprolol in the treatment of Chinese patients with mild to moderate hypertension. Primary objective: To evaluate the non-inferiority of nebivolol in antihypertensive efficacy compared with bisoprolol in the treatment of patients with mild to moderate essential hypertension. Secondary objective: To evaluate the safety of nebivolol compared with bisoprolol in patients with mild to moderate hypertension.

Start Date02 Dec 2020

Sponsor / Collaborator

A. Menarini China Holding Co., Ltd.

100 Clinical Results associated with A. Menarini China Holding Co., Ltd.

Login to view more data

0 Patents (Medical) associated with A. Menarini China Holding Co., Ltd.

Login to view more data

100 Deals associated with A. Menarini China Holding Co., Ltd.

Login to view more data

100 Translational Medicine associated with A. Menarini China Holding Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data